Recently a fully human monoclonal antibody directed against the IL-4 receptor α subunit (shared by the Type 1 and Type 2 IL-4 and IL-13 receptors, resulting in the blockage of both IL-4 and IL-13 signaling), called dupilumab (Regeneron Pharmaceuticals), has been shown to be highly effective for the treatment of moderate to severe adult AD subjects [15]. The gene discussed is IL13; the disease is Alzheimer disease.